Activated Recombinant Factor VII in Orthotopic Liver Transplantation

Pugliese, Francesco; Ruberto, Franco; Summonti, D; Perrella, S.; Cappannoli, A.; Tosi, Antonella; DaLio, Andrew L.; Bruno, Katelyn A.; Martelli, S.; Celli, Paolo; Morabito, Vincenzo; Rossi, Massimo; Berloco, P.; Pietropaoli, P

doi:10.1016/j.transproceed.2007.05.062

Cited by 37 publications

(22 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no difference in the rate of thromboembolic events between rFVIIa recipients and placebo in either study. However, more recently Pugliese et al [90] found that, in a randomized, doubleblind trial, patients underwent orthotopic liver transplantation who were preoperatively treated with a single bolus dose of rFVIIa 40 mg/kg received a lower total number of red blood units than placebo-treated patients.…”

Section: Liver Transplantationmentioning

confidence: 99%

The use of recombinant factor VIIa in liver diseases

Franchini

Montagnana²,

Targher³

et al. 2008

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Recombinant activated factor VII, a bypassing hemostatic agent originally developed for the treatment of hemorrhages in hemophilic patients with inhibitors, is increasingly being employed on a compassionate use basis for the treatment of uncontrolled massive bleeding from various causes. In this review, we present the current knowledge on the use of this agent in patients with severe coagulopathy due to end-stage liver disease. In particular, the role of recombinant activated factor VII for treating gastrointestinal bleeding episodes in patients with decompensated cirrhosis or for prophylaxis before liver surgical or invasive procedures will be addressed. The pathogenesis of complex coagulopathy in chronic liver diseases and the mechanisms by which recombinant activated factor VII might improve coagulation in such patients will also be described. Given the paucity of the published data and the lack of randomized trials, there is not enough evidence to support the extensive use of recombinant activated factor VII in any of the clinical indications analyzed. In conclusion, further large randomized, controlled clinical trials are needed to better define the role of recombinant activated factor VII in the treatment of bleeding complications of liver disorders.

show abstract

Section: Liver Transplantationmentioning

confidence: 99%

The use of recombinant factor VIIa in liver diseases

Franchini

Montagnana²,

Targher³

et al. 2008

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…If the correction of coagulopathy is necessary and adequate correction cannot be achieved with FFP, particularly in a volume overloaded patients, recombinant human factor VIIa should be considered. Recombinant factor VII (rFVIIa) helps to form as table clot by establishing complexes with exposed tissue factor, and it also enhances platelet activation [31] [32].…”

Section: Intensive Carementioning

confidence: 99%

Fulminant Hepatitis: Definitions, Causes and Management

Morabito¹,

Adebayo²

2014

Health

View full text Add to dashboard Cite

Fulminant hepatitis (FH) is a rare and devastating syndrome caused by a variety of hepatic insults. It characterized by severe metabolic derangements, neurologic complications and ultimately, multiorgan failure. Liver transplantation is the gold standard therapy for patients with irreversible FH. The major areas of current research in this field include the development of: hepatic support devices, strategies to accelerate hepatic regeneration and criteria for accurate prognostic classification of patients. This review aims to focus on the definitions, aetiologies and management strategies for FH.

show abstract

“…In coagulopathic patients with liver disease, most RCTs showed negative results; only one study could show a reduction in RBC transfusion requirements (Bosch et al 2004 ;Lodge et al 2005 ;Planinsic et al 2005 ;Pugliese et al 2007 ;Bosch et al 2008 ).…”

Section: Efficacy and Safetymentioning

confidence: 99%

Coagulation Factor Concentrates

Asmis¹

2014

Perioperative Hemostasis

View full text Add to dashboard Cite

Activated Recombinant Factor VII in Orthotopic Liver Transplantation

Cited by 37 publications

References 14 publications

The use of recombinant factor VIIa in liver diseases

The use of recombinant factor VIIa in liver diseases

Fulminant Hepatitis: Definitions, Causes and Management

Coagulation Factor Concentrates

Contact Info

Product

Resources

About